Go Back to tools
Sign Up The MASCC Risk Index
The MASCC Risk Index is used to assess for risk of serious complications of febrile neutropaenia in patients with cancer. Low risk patients (>21 points) may be safe for outpatient management, while high risk patients (
- ≥21 points: low risk of serious complications; consider oral antibiotics or outpatient management with IV antibiotics
- <21: High risk of serious complications; admit for IV antibiotics and close monitoring
References
Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L, Lalami Y, Aoun M, Barette M. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. Journal of clinical oncology. 2006 Sep 1;24(25):4129-34.Klastersky, J., Paesmans, M., Rubenstein, E.B., Boyer, M., Elting, L., Feld, R., Gallagher, J., Herrstedt, J., Rapoport, B., Rolston, K. and Talcott, J., 2000. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. Journal of Clinical Oncology, 18(16), pp.3038-3051.Worth LJ, Lingaratnam S, Taylor A, Hayward AM, Morrissey S, Cooney J, Bastick PA, Eek RW, Wei A, Thursky KA. Use of risk stratification to guide ambulatory management of neutropenic fever. Internal medicine journal. 2011 Jan;41(1b):82-9.